Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Bristol-Myers Company and Squibb Corporation announced a stock-for-stock merger of equals on July 27, 1989 valued at approximately $12-16 billion, closing October 4, 1989 to form Bristol-Myers Squibb Company. At the time, it was the largest pharmaceutical merger in US history and created one of the largest healthcare companies globally, with combined revenues of ~$8.9 billion. Bristol-Myers contributed a diversified portfolio across pharmaceuticals (Cefzil, Buspar), consumer health (Bufferin, Excedrin), Mead Johnson infant nutrition, and Clairol hair care. Squibb brought cardiovascular leadership anchored by Capoten (captopril — the first ACE inhibitor, ~$1.6B peak sales) and Monopril (fosinopril), plus oncology assets including early-stage paclitaxel (later launched as Taxol). Richard Gelb (ex-Bristol-Myers) served as chairman; Richard Furlaud (ex-Squibb) as vice-chairman. The merger pioneered the modern large-pharma consolidation era, preceding SmithKline/Beecham (1989), Glaxo/Burroughs Wellcome (1995), and the broader 1990s-2000s M&A wave.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Company / Squibb Corporation (this deal) | 1989 | $16.0B | 83 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 1989 deals · Cardiovascular deals